Crossmark

Real-World Success of Biologic Therapy in IBD: No More Reasons to Be Anti Antibody

Crossref DOI link: https://doi.org/10.1007/s10620-018-5385-9

Published Online: 2018-11-26

Published Print: 2019-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gordon, Neil

Sebastian, Shaji
License Information

Text and Data Mining valid from 2018-11-26
More Information

Article History

First Online: 26 November 2018

Compliance with ethical standards

:

: Professor Shaji Sebastian holds research grants from Takeda, AbbVie, Warner Chilcott, Ferring, MSD, serves on the advisory boards of Takeda, AbbVie, Merck, Ferring, Pharmacocosmos, Warner Chilcott, Janssen, Falk Pharma, Biohit, Tillots Pharma, and has received speaker fees from Abbvie, Jaansen, Merck, Warner Chilcott, and Falk Pharma. Neil Gordon has no conflicts to declare.